Prior immunosuppressant use? | Risk up to 24 months of natalizumab exposure | Risk after 24 months of natalizumab exposure | ||
JC virus antibody negative | No | ∼0.02/1000 | ∼0.2/1000 | |
Yes | ∼0.06/1000 | ∼0.9/1000 | ||
Risk up to 24 months of natalizumab exposure | Risk during 25 to 48 months of natalizumab exposure | Risk during 49 to 72 months of natalizumab exposure | ||
JC virus antibody positive | No, anti-JCV antibody index not available | ∼1/1000 | ∼3/1000 | ∼6/1000 |
No; anti-JCV antibody index ≤1.5 | ∼0.2/1000 | ∼1.1/1000 | ∼1.4/1000 | |
No; anti-JCV antibody index >1.5 | ∼1.2/1000 | ∼8.8/1000 | ∼10.1/1000 | |
Yes | ∼6/1000 | ∼12/1000 | ∼13/1000 |
Do you want to add Medilib to your home screen?